| Full of Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Reference and Education > College University > 4 Evaluation Factors Used in the IIM GD process |
|
Full of Articles - 4 Evaluation Factors Used in the IIM GD process
While it is important to have mock tests,you should
also have an idea of how to rank According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product your performance
to judge the level of improvement required. In the IIM MBA GD proce ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in s, the Group Discussion
and Personal Interview panel evaluates you based
on these f lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ctors: 1) Solutions: The quality of content is based upon your ability to create sol here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe tions. Most GD topics are
in the form of a question/problem to be solved; i.e.
Can d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ndia manage its fiscal deficit. Always make it a
point to have 3 points no more no le ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc s, ready to be
stated on how you feel the Fiscal deficit can be
managed less 2) Te easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi am player: Just because you know the topic
doesn't mean you should blabber non stop. nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ou will
get negative points for that. Like I said have 3 points
then encourage oth and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ r people to make their
viewpoints. The IIM GD process is an extension of
Corporate ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ecision making process, you should be
willing to play as a team, not act as if you ar ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a a one
man show. 3) Timeliness : Again why I stress 3 points are enough. The reten dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ion of the human mind does not
extend beyond 2 minutes of what you have said. The
I cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin M GD panel will remember only the key points
and then concentrate on other candidates tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen . Make
sure you get enough practice to say all your key
points within 2 minutes. 4 t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel Composure: Your body language will be
evaluated carefully. No touching of candidates ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust or
hand gestures that imply an attempt to FORCE
another candidate to shut up to lis y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products en to your
viewpoints. Be careful because you are being
monitored by some very smar . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de people who are
looking for an excuse to REJECT you. Remember
200 seats and 1000 ca elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip didates means you only get
one chance. Do not screw it up because of your
behaviour tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:4 Miscellaneous Email Marketing Advices Getting Past The Idea Of Budgeting & Saving Money Samsung E250 - Smooth Slide Through A Multimedia Extravaganza
|